# Intradermal COVID-19 Vaccination in the Immunocompromised

> **NCT05736913** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 130 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ID BNT162b2 vaccine
- **BIOLOGICAL:** IM BNT162b2 vaccine

## Key facts

- **NCT ID:** NCT05736913
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05736913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05736913, "Intradermal COVID-19 Vaccination in the Immunocompromised". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05736913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*